Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study
ConclusionRituximab is clinically effective in active forms of NMO, although few patients are resistant to the treatment.
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Brain | Disability | Leukemia | Neurology | Rituxan | Study